A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Hans C LeeJatin J ShahLei FengAshley MorpheyRalph J JohnsonEmily T WessonMichael L WangRaymond AlexanianSheeba K ThomasRobert Z OrlowskiDonna M WeberPublished in: American journal of hematology (2019)